cbr96-doxorubicin immunoconjugate cbr96-doxorubicin immunoconjugate cbr96-doxorubicin immunoconjugate (bms-182248/sgn-15; also known as cbr96-dox) is an antibody-drug conjugate or (adc) directed to the lewis-y antigen designed for the treatment of cancer. the payload is the chemotherapy drug doxorubicin which is connected with a hydrazone linker to cysteine residues of the lewis-y specific (chimeric) monoclonal antibody br96. following internalization, the hydrazone is hydrolyzed within the acidic environment of target cell endosomes and lysosomes to release active cytotoxic drug. cbr96-doxorubicin immunoconjugatemonoclonal antibodytype?sourcehumanized (from mouse)targetlewis-y antigenclinical dataother namessgn-15, bms-182248atc codenoneidentifierscas number160612-45-3chemspidernone clinical development in clinical trials cbr96-dox was found to be highly active in regressing large human tumor xenografts implanted in mice or rats. multiple tumor models including lung, breast and colon were evaluated, and cbr96-dox was found to have broad and potent anti-tumor activity, even in doxorubicin-resistant tumors.